BlackRock Technology and Private Equity Fund (BTX)
NYSE 
Summary
3 Big, Tax-Free Dividends To Anchor Your Tech Gains
Investors are flipping back into buy mode, which has been a boon to the equity funds—especially on the tech side.
BTX: Cannot Support Dividend Payouts
BlackRock Technology and Private Equity Term Trust maintains a hold rating due to ongoing performance and distribution sustainability concerns. BTX trades at a 14.64% discount to NAV and offers a 9.5% yield, but struggles to generate sufficient earnings for reliable payouts. The fund's heavy tech allocation, option writing strategy, and sensitivity to high-interest rates limit growth and increase risk.
BTX Offers Diversification Into Private Equity
BTX offers a unique blend of technology-focused public and private equity exposure with a high 12.96% yield. The fund's underperformance versus peer CEFs is likely driven by challenges in pricing private equity holdings, which may not realize value until public exit or sale. Distributions are primarily return of capital and can vary from period to period, impacting tax planning and income stability, making BTX less suitable for investors seeking predictable income.
BlackRock Technology and Private Equity Fund (BTX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has BlackRock Technology and Private Equity Fund ever had a stock split?
BlackRock Technology and Private Equity Fund Profile
| NYSE Exchange | US Country |
Overview
Brooklyn ImmunoTherapeutics, Inc. is a pioneering force in the realm of biopharmaceuticals, focusing its efforts on the development of innovative therapies aimed at treating cancer. Operating from its headquarters in Brooklyn, New York, this clinical stage company has carved out a niche for itself in the competitive field of oncology. With a passionate commitment to improving patient outcomes, Brooklyn ImmunoTherapeutics, Inc. is leading the charge in the exploration and utilization of next-generation therapeutic approaches, including gene editing and cell therapy technologies. By harnessing these cutting-edge methods, the company is not only targeting cancers but also venturing into the treatment of blood disorders and monogenic diseases, thereby broadening its impact on the medical community and those it serves.
Products and Services
- IRX-2
- Gene-Editing and Cell Therapy Technologies
This flagship product is at the forefront of Brooklyn ImmunoTherapeutics’ portfolio. Currently, in a Phase 2b clinical trial, IRX-2 is being tested for its efficacy in treating squamous cell cancer of the head and neck. This innovative therapeutic represents a significant step forward in the company’s commitment to offering new hope and potentially life-saving treatments to cancer patients. By focusing on this specific form of cancer, Brooklyn ImmunoTherapeutics underscores its dedication to addressing the unique challenges and needs within the oncology sphere.
In its quest to revolutionize cancer treatment, Brooklyn ImmunoTherapeutics is also developing an array of therapies employing gene-editing and cell therapy technologies. These groundbreaking approaches offer the potential for precise, personalized treatment modalities that could significantly alter the landscape of cancer care. Targeting not just oncology but also blood disorders and monogenic diseases, these technologies stand as a testament to the company’s innovative spirit and its relentless pursuit of therapeutic breakthroughs. Through these initiatives, Brooklyn ImmunoTherapeutics aims to unlock new possibilities in the treatment and management of a wide range of diseases, offering patients more effective and targeted options than ever before.
